Case Details

CourtDistrict of Delaware
Docket number1:15-cv-00150
Date case filed2015-02-11
Date case closed2017-06-09
Date of latest filing
Assigned toJudge Leonard P. Stark
Case cause35:145 Patent Infringement
Nature of suit830 Patent
Jury demandNone
Demand
JurisdictionFederal Question

Case Parties

Party: Novartis AG
Party type: Plaintiff
Attorney name: Michael P. Kelly
Attorney Contact:
McCarter & English, LLP
Renaissance Centre
405 N. King Street, 8th Floor
Wilmington, DE 19801
(302) 984-6301
Fax: (302) 984-6399
Email: [email protected]
LEAD ATTORNEY ATTORNEY TO BE NOTICED

Attorney name: Alexander N. Harris
Attorney Contact:
Email: [email protected]
PRO HAC VICE ATTORNEY TO BE NOTICED

Attorney name: Andrew Blythe
Attorney Contact:
Email: [email protected]
PRO HAC VICE ATTORNEY TO BE NOTICED

Attorney name: Barish Ozdamar
Attorney Contact:
UNDELIVERABLE EMAIL 6/27/2017
PRO HAC VICE ATTORNEY TO BE NOTICED

Attorney name: Beatrice Hahn
Attorney Contact:
Email: [email protected]
PRO HAC VICE ATTORNEY TO BE NOTICED

Attorney name: Benjamin A. Smyth
Attorney Contact:
McCarter & English, LLP
Renaissance Centre
405 N. King Street, 8th Floor
Wilmington, DE 19801
302-984-6300
Email: [email protected]
ATTORNEY TO BE NOTICED

Attorney name: Caitlin R. Looby
Attorney Contact:
Email: [email protected]
TERMINATED: 10/23/2015 PRO HAC VICE

Attorney name: Daniel M. Silver
Attorney Contact:
McCarter & English, LLP
Renaissance Centre
405 N. King Street, 8th Floor
Wilmington, DE 19801
(302) 984-6300
Fax: (302) 691-1260
Email: [email protected]
ATTORNEY TO BE NOTICED

Attorney name: Jane M. Love
Attorney Contact:
Email: [email protected]
PRO HAC VICE ATTORNEY TO BE NOTICED

Attorney name: Michael A. Valek
Attorney Contact:
Email: [email protected]
PRO HAC VICE ATTORNEY TO BE NOTICED

Attorney name: Nao Takada
Attorney Contact:
Email: [email protected]
TERMINATED: 12/05/2016 PRO HAC VICE ATTORNEY TO BE NOTICED

Attorney name: Paul J. Kremer
Attorney Contact:
Email: [email protected]
PRO HAC VICE ATTORNEY TO BE NOTICED

Attorney name: Robert W. Trenchard
Attorney Contact:
Email: [email protected]
PRO HAC VICE ATTORNEY TO BE NOTICED
Party: Novartis Pharmaceuticals Corporation
Party type: Plaintiff
Attorney name: Michael P. Kelly
Attorney Contact:
(See above for address)
LEAD ATTORNEY ATTORNEY TO BE NOTICED

Attorney name: Alexander N. Harris
Attorney Contact:
(See above for address)
PRO HAC VICE ATTORNEY TO BE NOTICED

Attorney name: Benjamin A. Smyth
Attorney Contact:
(See above for address)
ATTORNEY TO BE NOTICED

Attorney name: Daniel M. Silver
Attorney Contact:
(See above for address)
ATTORNEY TO BE NOTICED

Attorney name: Nao Takada
Attorney Contact:
(See above for address)
PRO HAC VICE ATTORNEY TO BE NOTICED
Party: Mitsubishi Tanabe Pharma Corporation
Party type: Plaintiff
Attorney name: Michael P. Kelly
Attorney Contact:
(See above for address)
LEAD ATTORNEY ATTORNEY TO BE NOTICED

Attorney name: Benjamin A. Smyth
Attorney Contact:
(See above for address)
ATTORNEY TO BE NOTICED

Attorney name: Daniel M. Silver
Attorney Contact:
(See above for address)
ATTORNEY TO BE NOTICED

Attorney name: Nao Takada
Attorney Contact:
(See above for address)
PRO HAC VICE ATTORNEY TO BE NOTICED
Party: Mitsui Sugar Co. Ltd.
Party type: Plaintiff
Attorney name: Michael P. Kelly
Attorney Contact:
(See above for address)
LEAD ATTORNEY ATTORNEY TO BE NOTICED

Attorney name: Benjamin A. Smyth
Attorney Contact:
(See above for address)
ATTORNEY TO BE NOTICED

Attorney name: Daniel M. Silver
Attorney Contact:
(See above for address)
ATTORNEY TO BE NOTICED

Attorney name: Nao Takada
Attorney Contact:
(See above for address)
PRO HAC VICE ATTORNEY TO BE NOTICED
Party: Ezra Ventures LLC
Party type: Defendant
Attorney name: Stamatios Stamoulis
Attorney Contact:
Stamoulis & Weinblatt LLC
Two Fox Point Centre
6 Denny Road, Suite 307
Wilmington, DE 19809
(302) 999-1540
Email: [email protected]
LEAD ATTORNEY ATTORNEY TO BE NOTICED

Attorney name: Brent A. Batzer
Attorney Contact:
Email: [email protected]
PRO HAC VICE ATTORNEY TO BE NOTICED

Attorney name: Joseph E. Cwik
Attorney Contact:
Email: [email protected]
PRO HAC VICE ATTORNEY TO BE NOTICED

Attorney name: Shashank T. Upadhye
Attorney Contact:
Email: [email protected]
PRO HAC VICE ATTORNEY TO BE NOTICED

Attorney name: Yixin H. Tang
Attorney Contact:
Email: [email protected]
PRO HAC VICE ATTORNEY TO BE NOTICED

Case Docket

Docket
Item
Date FiledDocument
Available
Short
Description
Long Description
12015-02-11 COMPLAINT filed against Ezra Ventures LLC - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1673580.) - filed by Novartis AG, Mitsui Sugar Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(mas, ) (Entered: 02/12/2015)
1.1 Exhibit A
1.2 Civil Cover Sheet
22015-02-11 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mas, ) (Entered: 02/12/2015)
32015-02-11 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 1/2/15. Date of Expiration of Patent: 2/18/19.Thirty Month Stay Deadline: 3/21/2018. (mas, ) (Entered: 02/12/2015)
42015-02-11 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,604,229;. (mas, ) (Entered: 02/12/2015)
52015-02-11 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Novartis AG. (mas, ) (Entered: 02/12/2015)
62015-02-11 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (mas, ) (Entered: 02/12/2015)
72015-02-11 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Mitsubishi Chemical Holdings Corporation for Mitsubishi Tanabe Pharma Corporation filed by Mitsubishi Tanabe Pharma Corporation. (mas, ) (Entered: 02/12/2015)
82015-02-11 Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Mitsui & Co Ltd. for Mitsui Sugar Co. Ltd. filed by Mitsui Sugar Co. Ltd.. (mas, ) (Entered: 02/12/2015)
92015-02-13 DECLARATION of Mailing regarding service on Ezra Ventures, LLC made on February 12, 2015 by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Ex. A & Ex. B)(Smyth, Benjamin) (Entered: 02/13/2015)
102015-03-03 STIPULATION TO EXTEND TIME to Answer Complaint to April 6, 2015 - filed by Ezra Ventures LLC. (Stamoulis, Stamatios) (Entered: 03/03/2015)
112015-03-11 MOTION for Pro Hac Vice Appearance of Attorney Shashank Upadhye, Joseph E. Cwik, and Jonathan Krit - filed by Ezra Ventures LLC. (Attachments: # 1 Certificate of Compliance Upadhye, # 2 Certificate of Compliance Cwik, # 3 Certificate of Compliance Krit)(Stamoulis, Stamatios) (Entered: 03/11/2015)
122015-03-19 MOTION for Pro Hac Vice Appearance of Attorney Jane M. Love, Robert Trenchard, Kevin S. Prussia and Caitlin R. Looby - filed by Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certifications for Jane M. Love, Robert Trenchard, Kevin S. Prussia & Caitlin R. Looby)(Silver, Daniel) (Entered: 03/19/2015)
132015-04-02 MOTION to Dismiss for Lack of Jurisdiction Over the Person - filed by Ezra Ventures LLC. (Attachments: # 1 Text of Proposed Order)(Stamoulis, Stamatios) (Entered: 04/02/2015)
142015-04-02 OPENING BRIEF in Support re 13 MOTION to Dismiss for Lack of Jurisdiction Over the Person [MEMORANDUM IN SUPPORT OF EZRA VENTURES LLC'S MOTION TO DISMISS FOR LACK OF PERSONAL JURISDICTION OR IN THE ALTERNATIVE MOTION TO TRANSFER VENUE] filed by Ezra Ventures LLC.Answering Brief/Response due date per Local Rules is 4/20/2015. (Stamoulis, Stamatios) (Entered: 04/02/2015)
152015-04-02 DECLARATION re 13 MOTION to Dismiss for Lack of Jurisdiction Over the Person [DECLARATION OF MICHAEL GERANEN IN SUPPORT OF EZRA'S MOTION TO DISMISS] by Ezra Ventures LLC. (Stamoulis, Stamatios) (Entered: 04/02/2015)
162015-04-16 Joint Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding requesting teleconference to resolve dispute between the parties. (Silver, Daniel) (Entered: 04/16/2015)
172015-04-20 [SEALED] ANSWERING BRIEF in Opposition re 13 MOTION to Dismiss for Lack of Jurisdiction Over the Person filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 4/30/2015. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 04/20/2015)
182015-04-20 [SEALED] DECLARATION re 17 Answering Brief in Opposition, Declaration of Kristen Smith-Harrington by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 04/20/2015)
192015-04-20 DECLARATION re 17 Answering Brief in Opposition, Declaration of Caitlin R. Looby by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A)(Silver, Daniel) (Entered: 04/20/2015)
202015-04-27 REDACTED VERSION of 17 Answering Brief in Opposition, by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 04/27/2015)
212015-04-27 REDACTED VERSION of 18 Declaration, by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 04/27/2015)
222015-04-30 ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for May 12, 2015 at 4:30 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than May 6, 2015, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than May 7, 2015, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 4/30/15. Associated Cases: 1:15-cv-00150-LPS, 1:15-cv-00151-LPS (ntl) (Entered: 04/30/2015)
232015-05-01 MOTION for Extension of Time to File Response/Reply as to 13 MOTION to Dismiss for Lack of Jurisdiction Over the Person - filed by Ezra Ventures LLC. (Attachments: # 1 Exhibit A - Reply Brief, # 2 Exhibit B - Email Correspondence, # 3 Exhibit C - Email Correspondence, # 4 Text of Proposed Order)(Stamoulis, Stamatios) (Entered: 05/01/2015)
242015-05-05 NOTICE of Non-Opposition of Defendant's Motion for One-Day Extension of Time to File Reply Brief by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation (Silver, Daniel) (Entered: 05/05/2015)
252015-05-06 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. - re (24 in 1:15-cv-00151-LPS, 22 in 1:15-cv-00150-LPS) Order Setting Teleconference,,,,. (Attachments: # 1 Exhibit A)(Silver, Daniel) (Entered: 05/06/2015)
262015-05-07 Letter to Chief Judge Leonard P. Stark from Stamatios Stamoulis regarding responding to Plaintiffs' letter - re 25 Letter. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Stamoulis, Stamatios) (Entered: 05/07/2015)
272015-05-11 ORAL ORDER: Having reviewed the parties' letters regarding discovery and scheduling (D.I. 25, 26), and having reviewed the parties' briefing regarding the pending motion to dismiss for lack of personal jurisdiction (see D.I. 13), IT IS HEREBY ORDERED that: (1) Defendant's motion (D.I. 13) is DENIED WITHOUT PREJUDICE to renew after the Federal Circuit Court of Appeals issues its decision in the pending interlocutory appeals that will likely address similar if not identical matters as presented by Defendant's motion (see D.I. 23-1 at 9); (2) Defendant's alternative relief transferring venue in favor of a second-filed action or staying the case - is also DENIED, as unwarranted, for reasons including that discovery will be needed wherever and whenever this case proceeds and there is no persuasive reason for further delay; (3) Defendant's unopposed motion for extension of time to file reply brief (D.I. 23) is GRANTED; (4) the Court will issue an order soliciting scheduling proposals in this and the related cases; and (5) the teleconference scheduled for tomorrow is CANCELLED. ORDERED by Judge Leonard P. Stark on 5/11/15. (ntl) (Entered: 05/11/2015)
282015-05-11 ORAL ORDER: IT IS HEREBY ORDERED that the parties shall confer regarding proposed dates in the scheduling order and shall submit a proposal, including a proposal for the length and timing of trial, to the Court no later than May 29, 2015. The parties are to review the Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Judge Stark, New Patent Procedures). ORDERED by Judge Leonard P. Stark on 5/11/15. Associated Cases: 1:14-cv-01487-LPS, 1:15-cv-00150-LPS, 1:15-cv-00151-LPS (ntl) (Entered: 05/11/2015)
292015-05-11 REPLY to Response to Motion re 13 MOTION to Dismiss for Lack of Jurisdiction Over the Person filed by Ezra Ventures LLC. (Stamoulis, Stamatios) (Entered: 05/11/2015)
302015-05-21 MOTION for Certificate of Appealability [MOTION FOR CERTIFICATION FOR INTERLOCUTORY APPEAL AND CORRESPONDING WRITTEN ORDER] - filed by Ezra Ventures LLC. (Attachments: # 1 Text of Proposed Order)(Stamoulis, Stamatios) (Entered: 05/21/2015)
312015-05-21 MEMORANDUM in Support re 30 MOTION for Certificate of Appealability [MOTION FOR CERTIFICATION FOR INTERLOCUTORY APPEAL AND CORRESPONDING WRITTEN ORDER] filed by Ezra Ventures LLC.Answering Brief/Response due date per Local Rules is 6/8/2015. (Stamoulis, Stamatios) (Entered: 05/21/2015)
322015-05-27 ANSWER to 1 Complaint, [EZRA VENTURES, LLC'S ANSWER, AFFIRMATIVE DEFENSES, AND COUNTERCLAIMS] by Ezra Ventures LLC.(Stamoulis, Stamatios) (Entered: 05/27/2015)
332015-05-29 Proposed MOTION for Scheduling Order - filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 05/29/2015)
342015-06-02 ORAL ORDER: IT IS HEREBY ORDERED that the Court will hold a status teleconference in these two related cases on June 22, 2015 beginning at 9:00 a.m., which will include discussion of the motions to certify for interlocutory appeal and the HEC Defendants request for clarification of the Courts order. Counsel for the Defendants shall initiate the call to (302) 573-4573. ORDERED by Judge Leonard P. Stark on 6/2/15. Associated Cases: 1:15-cv-00150-LPS, 1:15-cv-00151-LPS (ntl) (Entered: 06/02/2015)
352015-06-02 ORDER re 23 MOTION for Extension of Time to File Reply as to 13 MOTION to Dismiss filed by Ezra Ventures LLC. Signed by Judge Leonard P. Stark on 6/1/15. (ntl) (Entered: 06/02/2015)
362015-06-03 NOTICE OF SERVICE of Plaintiffs' First Set of Common Requests for the Production of Documents and Things to All Defendants filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 06/03/2015)
372015-06-08 ANSWERING BRIEF in Opposition re 30 MOTION for Certificate of Appealability [MOTION FOR CERTIFICATION FOR INTERLOCUTORY APPEAL AND CORRESPONDING WRITTEN ORDER] filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 6/18/2015. (Attachments: # 1 Exhibit A)(Silver, Daniel) (Entered: 06/08/2015)
382015-06-18 REPLY BRIEF re 30 MOTION for Certificate of Appealability [MOTION FOR CERTIFICATION FOR INTERLOCUTORY APPEAL AND CORRESPONDING WRITTEN ORDER] filed by Ezra Ventures LLC. (Stamoulis, Stamatios) (Entered: 06/18/2015)
392015-06-22 OBJECTIONS by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation to 32 Answer to Complaint Plaintiffs' Answer to Ezra's Counterclaims. (Silver, Daniel) (Entered: 06/22/2015)
402015-06-23 ORAL ORDER: For the reasons stated during yesterday's teleconference, it is HEREBY ORDERED that Defendant's Motion for Certification for Interlocutory Appeal and Corresponding Written Order (D.I. 30) is DENIED. It is FURTHER HEREBY ORDERED that, within seven (7) days of the Federal Circuit reaching a decision in the appeal of either the Acorda case (C.A. No. 14-935-LPS) or the AstraZeneca case (C.A. No. 14-696-GMS), whichever is sooner, the parties SHALL meet and confer and submit a joint status report indicating: (1) whether Defendant intends to file a renewed motion to dismiss; (2) if so, whether Plaintiffs intend to oppose such a motion; and (3) if so, on what schedule the parties propose to expeditiously and succinctly brief such a motion. ORDERED by Judge Leonard P. Stark on 6/23/15. (ntl) (Entered: 06/23/2015)
412015-06-24 SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. These cases shall be coordinated for all pre-trial purposes. The parties are to file all papers in the lead case docket 14-1487-LPS except for issues limited to a specific Defendant(s), which shall be filed only on the appropriate docket(s). Discovery due by 6/7/2016. Status Report due by 3/8/2016. Claim Construction Opening Brief due by 3/15/2016. Claim Construction Answering Brief due by 4/19/2016. Claim Construction Reply Brief due by 5/3/2016. Claim Construction Surreply Brief due by 5/10/2016. A Markman Hearing is set for 6/6/2016 at 01:00 PM in Courtroom 6B before Judge Leonard P. Stark. A Final Pretrial Conference is set for 3/10/2017 at 09:00 AM in Courtroom 6B before Judge Leonard P. Stark. Proposed Pretrial Order due by 2/27/2017. A 4-day Bench Trial is set for 3/20/2017 at 08:30 AM in Courtroom 6B before Judge Leonard P. Stark. Signed by Judge Leonard P. Stark on 6/23/15. Associated Cases: 1:14-cv-01487-LPS, 1:15-cv-00150-LPS, 1:15-cv-00151-LPS (ntl) (Entered: 06/24/2015)
422015-06-26 NOTICE OF SERVICE of Plaintiffs' Initial Disclosures Pursuant to Fed.R.Civ.P. 26(a)(1) and Plaintiff's Initial Disclosures Pursuant to Order for Discovery of Electronically-Stored Information ("ESI") filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 06/26/2015)
432015-06-26 NOTICE OF SERVICE of Defendants' First Set of Common Requests for the Production of Documents and Things to Plaintiffs (Nos. 1-70) and Defendants' First Set of Common Interrogatories to Plaintiffs (Nos. 1-13) filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC.(Vrana, Robert) (Entered: 06/26/2015)
442015-06-26 NOTICE OF SERVICE of (1) Rule 26(a)(1) Disclosures; and (2) Initial Disclosures under Paragraph 3 of Delaware's Default Standard for Discovery filed by Ezra Ventures LLC.(Stamoulis, Stamatios) (Entered: 06/26/2015)
452015-07-06 STIPULATION TO EXTEND TIME to submit Responses and Objections to Plaintiffs' First Set of Common Requests for Production to July 10, 2015 - filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC. (Vrana, Robert) (Entered: 07/06/2015)
462015-07-10 NOTICE OF SERVICE of EZRA'S RESPONSES AND OBJECTIONS TO PLAINTIFFS' FIRST SET OF REQUESTS FOR PRODUCTION (1-68) filed by Ezra Ventures LLC.(Stamoulis, Stamatios) (Entered: 07/10/2015)
472015-07-13 STIPULATION TO EXTEND TIME to Submit a Proposed [Stipulated] Protective Order to July 17, 2015 - filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC. (Vrana, Robert) (Entered: 07/13/2015)
482015-07-15 Official Transcript of Status Telephone Conference held on June 22, 2015 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 8/5/2015. Redacted Transcript Deadline set for 8/17/2015. Release of Transcript Restriction set for 10/13/2015. (bpg) (Entered: 07/15/2015)
492015-07-29 NOTICE OF SERVICE of EZRA'S FIRST SET OF INDIVIDUAL INTERROGATORIES (NOS. 1-3) filed by Ezra Ventures LLC.(Stamoulis, Stamatios) (Entered: 07/29/2015)
502015-07-31 NOTICE OF SERVICE of Defendants' Second Set of Common Interrogatories to Plaintiffs (Nos. 14-15) filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC.(Vrana, Robert) (Entered: 07/31/2015)
512015-08-31 NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendant Ezra's First Set of Individual Interrogatories (Nos. 1-3) filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 08/31/2015)
522015-09-01 NOTICE OF SERVICE of Plaintiffs' Preliminary Infringement Contentions for Defendants filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 09/01/2015)
532015-09-04 NOTICE of Change of Law Firm Affiliation for Jane M. Love and Robert Trenchard by Novartis AG, Novartis Pharmaceuticals Corporation (Silver, Daniel) (Entered: 09/04/2015)
542015-09-30 NOTICE OF SERVICE of (1) Plaintiffs' First Set of Common Interrogatories to All Defendants and (2) Plaintiffs' First Set of Interrogatories to Defendants filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 09/30/2015)
552015-10-08 STIPULATION TO EXTEND TIME the Schedule for Serving Infringement and Invalidity Contentions to (see stipulation for details) - filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 10/08/2015)
562015-10-16 ORDER Setting Mediation Conference: A Telephone Conference is set for 11/16/2015 at 11:30 AM before Judge Christopher J. Burke. Signed by Judge Christopher J. Burke on 10/16/2015. Associated Cases: 1:14-cv-01487-LPS, 1:15-cv-00150-LPS, 1:15-cv-00151-LPS(dlk) (Entered: 10/16/2015)
572015-10-22 NOTICE requesting Clerk to remove Wilmer Cutler Pickering Hale and Dorr LLP as co-counsel.. (Silver, Daniel) (Entered: 10/22/2015)
582015-11-02 NOTICE OF SERVICE of EZRA VENTURES, LLC'S RESPONSES AND OBJECTIONS TO PLAINTIFFS' FIRST SET OF INTERROGATORIES TO EZRA VENTURES, LLC filed by Ezra Ventures LLC.(Stamoulis, Stamatios) (Entered: 11/02/2015)
592015-11-04 NOTICE OF SERVICE of Defendants' Responses and Objections to Plaintiffs' First Set of Common Interrogatories to All Defendants filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC.(Vrana, Robert) (Entered: 11/04/2015)
602015-12-14 MOTION to Dismiss Based upon [Defendants' Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing] - filed by Ezra Ventures LLC. (Attachments: # 1 Rule 7.1 Statement)(Vrana, Robert) (Entered: 12/14/2015)
612015-12-14 [SEALED] OPENING BRIEF in Support re 60 MOTION to Dismiss Based upon [Defendants' Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing] filed by Ezra Ventures LLC.Answering Brief/Response due date per Local Rules is 12/31/2015. (Attachments: # 1 Certificate of Service)(Vrana, Robert) (Entered: 12/14/2015)
622015-12-15 [SEALED] EXHIBIT re 61 Opening Brief in Support, [Exhibits A - I to Defendants' Opening Brief in Support of Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing] by Ezra Ventures LLC. (Attachments: # 1 Exhibit A, Part 2, # 2 Exhibit A, Part 3, # 3 Exhibit A, Part 4, # 4 Exhibit B - D, # 5 Exhibit E - I, # 6 Exhibit J - O, # 7 Exhibit Certificate of Service)(Vrana, Robert) (Entered: 12/15/2015)
632015-12-21 REDACTED VERSION of (83 in 1:15-cv-00151-LPS) Opening Brief in Support, (61 in 1:15-cv-00150-LPS) Opening Brief in Support, (63 in 1:14-cv-01487-LPS) Opening Brief in Support, by Actavis Elizabeth LLC, Actavis Inc.. (Vrana, Robert) (Entered: 12/21/2015)
642015-12-21 REDACTED VERSION of (84 in 1:15-cv-00151-LPS) Exhibit to a Document, (62 in 1:15-cv-00150-LPS) Exhibit to a Document, (64 in 1:14-cv-01487-LPS) Exhibit to a Document,, EXHIBITS A O TO DEFENDANTS OPENING BRIEF IN SUPPORT OF MOTION TO DISMISS by Actavis Elizabeth LLC, Actavis Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B - O)(Vrana, Robert) (Entered: 12/21/2015)
652015-12-22 NOTICE OF SERVICE of PLAINTIFFS' RESPONSES TO DEFENDANTS' INVALIDITY CONTENTIONS filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 12/22/2015)
662015-12-29 NOTICE OF SERVICE of EZRA'S RESPONSES AND OBJECTIONS TO PLAINTIFFS' SECOND SET OF REQUESTS FOR PRODUCTION (69-73) filed by Ezra Ventures LLC.(Stamoulis, Stamatios) (Entered: 12/29/2015)
672016-01-04 NOTICE OF SERVICE of HEC Pharma Co., Ltd. and HEC Pharma USA, Inc.s Objections and Responses to Plaintiffs Second Common Request for Production (68-73) filed by HEC Pharm Co. Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) (Entered: 01/04/2016)
682016-01-06 First PROPOSED ORDER Amended [Proposed] Protective Order re (35 in 1:14-cv-01487-LPS) Proposed Order by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation, Mitsui Sugar Co., Ltd.. (Silver, Daniel) (Entered: 01/06/2016)
692016-01-06 NOTICE OF SERVICE of EZRA VENTURES, LLC'S RESPONSES AND OBJECTIONS TO PLAINTIFFS' SECOND SET OF INTERROGATORIES TO EZRA VENTURES, LLC filed by Ezra Ventures LLC.(Stamoulis, Stamatios) (Entered: 01/06/2016)
702016-01-25 MOTION for Judgment on the Pleadings under FRCP 12(c) - filed by Ezra Ventures LLC. (Stamoulis, Stamatios) (Entered: 01/25/2016)
712016-01-25 OPENING BRIEF in Support re 70 MOTION for Judgment on the Pleadings under FRCP 12(c) filed by Ezra Ventures LLC.Answering Brief/Response due date per Local Rules is 2/11/2016. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D-1, # 5 Exhibit D-2, # 6 Exhibit D-3, # 7 Exhibit D-4, # 8 Exhibit D-5)(Stamoulis, Stamatios) (Entered: 01/25/2016)
722016-01-25 PROPOSED ORDER re 70 MOTION for Judgment on the Pleadings under FRCP 12(c) by Ezra Ventures LLC. (Stamoulis, Stamatios) (Entered: 01/25/2016)
732016-02-01 STIPULATION TO EXTEND TIME for Plaintiffs to file their Answering Brief in Opposition to Defendants Motion for Judgment on the Pleadings under FRCP 12(c) to Thursday, February 25, 2016 - filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 02/01/2016)
742016-02-01 [SEALED] ANSWERING BRIEF in Opposition re 60 MOTION to Dismiss Based upon [Defendants' Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing] filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 2/11/2016. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Additional attachment(s) added on 2/2/2016: # 2 Main Document) (rpg). (Entered: 02/01/2016)
752016-02-01 [SEALED] DECLARATION re (74 in 1:15-cv-00150-LPS) Answering Brief in Opposition, (98 in 1:15-cv-00151-LPS) Answering Brief in Opposition, (75 in 1:14-cv-01487-LPS) Answering Brief in Opposition, Declaration of Ryoji Hirose In Opposition to Defendant's Motion to Dismiss by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 02/01/2016)
762016-02-01 [SEALED] DECLARATION re (74 in 1:15-cv-00150-LPS) Answering Brief in Opposition, (98 in 1:15-cv-00151-LPS) Answering Brief in Opposition, (75 in 1:14-cv-01487-LPS) Answering Brief in Opposition, Declaration of Hiromi Okatake In Opposition to Defendant's Motion to Dismiss by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 02/01/2016)
772016-02-01 [SEALED] DECLARATION re (74 in 1:15-cv-00150-LPS) Answering Brief in Opposition, (98 in 1:15-cv-00151-LPS) Answering Brief in Opposition, (75 in 1:14-cv-01487-LPS) Answering Brief in Opposition, Declaration of Judge Toshiaki Iimura In Opposition to Defendants' Motion to Dismiss by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 02/01/2016)
782016-02-01 [SEALED] DECLARATION re (74 in 1:15-cv-00150-LPS) Answering Brief in Opposition, (98 in 1:15-cv-00151-LPS) Answering Brief in Opposition, (75 in 1:14-cv-01487-LPS) Answering Brief in Opposition, Declaration of Robert W. Trenchard In Opposition to Defendants' Motion to Dismiss by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A-C, # 2 Exhibit D, # 3 Exhibit E-G, # 4 Exhibit H-K, # 5 Exhibit L-M, # 6 Certificate of Service)(Silver, Daniel) (Entered: 02/01/2016)
792016-02-01 [SEALED] DECLARATION re (74 in 1:15-cv-00150-LPS) Answering Brief in Opposition, (98 in 1:15-cv-00151-LPS) Answering Brief in Opposition, (75 in 1:14-cv-01487-LPS) Answering Brief in Opposition, Declaration of Peter J. Waibel, Esq. In Opposition to Defendants' Motion to Dismiss by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 02/01/2016)
802016-02-09 REDACTED VERSION of (74 in 1:15-cv-00150-LPS) Answering Brief in Opposition,, (98 in 1:15-cv-00151-LPS) Answering Brief in Opposition,, (75 in 1:14-cv-01487-LPS) Answering Brief in Opposition,, by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 02/09/2016)
812016-02-09 REDACTED VERSION of (75 in 1:15-cv-00150-LPS, 76 in 1:14-cv-01487-LPS, 99 in 1:15-cv-00151-LPS) Declaration, by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 02/09/2016)
822016-02-09 REDACTED VERSION of (77 in 1:14-cv-01487-LPS, 100 in 1:15-cv-00151-LPS, 76 in 1:15-cv-00150-LPS) Declaration, by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 02/09/2016)
832016-02-09 REDACTED VERSION of (78 in 1:14-cv-01487-LPS, 101 in 1:15-cv-00151-LPS, 77 in 1:15-cv-00150-LPS) Declaration, by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 02/09/2016)
842016-02-09 REDACTED VERSION of (78 in 1:15-cv-00150-LPS, 79 in 1:14-cv-01487-LPS, 102 in 1:15-cv-00151-LPS) Declaration,, by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A-F, # 2 Exhibit G, # 3 Exhibit H-M)(Silver, Daniel) (Entered: 02/09/2016)
852016-02-09 REDACTED VERSION of (80 in 1:14-cv-01487-LPS, 79 in 1:15-cv-00150-LPS, 103 in 1:15-cv-00151-LPS) Declaration, by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 02/09/2016)
862016-02-11 STIPULATION TO EXTEND TIME for Defendants to File their Reply Brief in Support of their Motion to Dismiss to February 25, 2016 - filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC. (Vrana, Robert) (Entered: 02/11/2016)
872016-02-17 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Scheduling a Discovery Teleconference. (Silver, Daniel) (Entered: 02/17/2016)
882016-02-18 STIPULATION TO EXTEND TIME for Plaintiffs to file their Answering Brief in Opposition to Defendants Motion for Judgment on the Pleadings under FRCP 12(c) to Monday, February 29, 2016 (from Tuesday, February 25, 2016) - filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 02/18/2016)
892016-02-23 ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for March 4, 2016 at 4:15 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than February 25, 2016, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than February 29, 2016, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 2/23/16. Associated Cases: 1:14-cv-01487-LPS, 1:15-cv-00150-LPS, 1:15-cv-00151-LPS, 1:15-cv-00975-LPS (ntl) (Entered: 02/23/2016)
902016-02-23 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Joint Claim Chart. (Silver, Daniel) (Entered: 02/23/2016)
912016-02-24 Letter to The Honorable Leonard P. Stark from Robert M. Vrana, Esq. regarding request for scheduling of a discovery teleconference on pending discovery disputes. (Vrana, Robert) (Entered: 02/24/2016)
922016-02-25 STIPULATION TO EXTEND TIME for Defendants to File Reply Brief in support of their Motion to Dismiss to March 10, 2016 - filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC. (Vrana, Robert) (Entered: 02/25/2016)
932016-02-25 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Privilege Log - re (27 in 1:15-cv-00975-LPS, 114 in 1:15-cv-00151-LPS, 89 in 1:14-cv-01487-LPS, 89 in 1:15-cv-00150-LPS) Order Setting Teleconference,,,,. (Attachments: # 1 Exhibit A)(Silver, Daniel) (Entered: 02/25/2016)
942016-02-25 [SEALED] Letter to The Honorable Leonard P. Stark from Robert M. Vrana, Esq. regarding Discovery Disputes Related to Defendants' Motion to Dismiss. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Vrana, Robert) (Entered: 02/25/2016)
952016-02-26 ORAL ORDER: Having reviewed the parties' letter regarding additional discovery disputes (see C.A. No. 14-1487 D.I. 91), IT IS HEREBY ORDERED that: (i) the discovery teleconference scheduled for March 4 is RESCHEDULED for March 11, 2016 beginning at 10:00 a.m.; (ii) the letters due on Monday, February 29 remain due on that day; and (iii) the parties' letters to be filed in connection with the discovery disputes referenced in the new letter shall be filed on March 2 and March 4. ORDERED by Judge Leonard P. Stark on 2/26/16. Associated Cases: 1:14-cv-01487-LPS, 1:15-cv-00150-LPS, 1:15-cv-00151-LPS, 1:15-cv-00975-LPS (ntl) (Entered: 02/26/2016)
962016-02-29 ANSWERING BRIEF in Opposition re 70 MOTION for Judgment on the Pleadings under FRCP 12(c) filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation.Reply Brief due date per Local Rules is 3/10/2016. (Silver, Daniel) (Entered: 02/29/2016)
972016-02-29 DECLARATION re 96 Answering Brief in Opposition, OF JANE M. LOVE, PH.D. by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A Pt. 1, # 2 Exhibit A Pt. 2, # 3 Exhibit B-D, # 4 Exhibit E Pt.1, # 5 Exhibit E Pt.2, # 6 Exhibit E Pt.3, # 7 Exhibit E Pt.4, # 8 Exhibit F-H)(Silver, Daniel) (Entered: 02/29/2016)
982016-02-29 Letter to The Honorable Leonard P. Stark from David E. Moore, Esquire regarding response to Plaintiffs' letter regarding privilege log - re (32 in 1:15-cv-00975-LPS, 93 in 1:15-cv-00150-LPS, 93 in 1:14-cv-01487-LPS, 117 in 1:15-cv-00151-LPS) Letter,. (Moore, David) (Entered: 02/29/2016)
992016-03-02 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. - re (34 in 1:15-cv-00975-LPS, 119 in 1:15-cv-00151-LPS, 95 in 1:14-cv-01487-LPS, 95 in 1:15-cv-00150-LPS) Order Setting Teleconference,,. (Silver, Daniel) (Entered: 03/02/2016)
1002016-03-02 [SEALED] Letter to The Honorable Leonard P. Stark from Robert M. Vrana, Esq. regarding Discovery Disputes Related to Defendants' Motion to Dismiss - re (34 in 1:15-cv-00975-LPS, 119 in 1:15-cv-00151-LPS, 95 in 1:14-cv-01487-LPS, 95 in 1:15-cv-00150-LPS) Order Setting Teleconference,,. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Vrana, Robert) (Entered: 03/02/2016)
1012016-03-03 REDACTED VERSION of (94 in 1:14-cv-01487-LPS, 118 in 1:15-cv-00151-LPS, 94 in 1:15-cv-00150-LPS, 33 in 1:15-cv-00975-LPS) Letter to The Honorable Leonard P. Stark from Robert M. Vrana, Esq. regarding Discovery Disputes Related to Defendants' Motion to Dismiss by Actavis Elizabeth LLC, Actavis Inc.. (Vrana, Robert) (Entered: 03/03/2016)
1022016-03-03 REDACTED VERSION of (37 in 1:15-cv-00975-LPS, 100 in 1:15-cv-00150-LPS, 98 in 1:14-cv-01487-LPS, 124 in 1:15-cv-00151-LPS) Letter, Letter to The Honorable Leonard P. Stark from Robert M. Vrana, Esq. regarding Discovery Disputes Related to Defendants' Motion to Dismiss by Actavis Elizabeth LLC, Actavis Inc.. (Vrana, Robert) (Entered: 03/03/2016)
1032016-03-04 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding response to defendants March 2, 2016 discovery dispute letter - re (34 in 1:15-cv-00975-LPS, 119 in 1:15-cv-00151-LPS, 95 in 1:14-cv-01487-LPS, 95 in 1:15-cv-00150-LPS) Order Setting Teleconference,,. (Attachments: # 1 Exhibit A)(Silver, Daniel) (Entered: 03/04/2016)
1042016-03-04 [SEALED] Letter to The Honorable Leonard P. Stark from Robert M. Vrana, Esq. regarding Response to Plaintiffs' March 2, 2016 Letter on Discovery Disputes Relating to Defendants' Motion to Dismiss - re (36 in 1:15-cv-00975-LPS, 99 in 1:15-cv-00150-LPS, 97 in 1:14-cv-01487-LPS, 123 in 1:15-cv-00151-LPS) Letter. (Vrana, Robert) (Entered: 03/04/2016)
1052016-03-07 REPLY BRIEF re 70 MOTION for Judgment on the Pleadings under FRCP 12(c) filed by Ezra Ventures LLC. (Stamoulis, Stamatios) (Entered: 03/07/2016)
1062016-03-07 REQUEST for Oral Argument by Ezra Ventures LLC re 70 MOTION for Judgment on the Pleadings under FRCP 12(c). (Stamoulis, Stamatios) (Entered: 03/07/2016)
1072016-03-08 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Joint Interim Status Report. (Silver, Daniel) (Entered: 03/08/2016)
1082016-03-09 REDACTED VERSION of (104 in 1:15-cv-00150-LPS, 42 in 1:15-cv-00975-LPS, 102 in 1:14-cv-01487-LPS, 129 in 1:15-cv-00151-LPS) Letter, to The Honorable Leonard P. Stark from Robert M. Vrana, Esq. regarding Response to Plaintiffs' March 2, 2016 Letter on Discovery Disputes Relating to Defendants' Motion to Dismiss by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC. (Vrana, Robert) (Entered: 03/09/2016)
1092016-03-09 STIPULATION TO EXTEND TIME for Defendants to File Their Reply Brief in Support of Their Motion to Dismiss to a Date to be Determined Pending the Outcome of the March 11, 2016 Discovery Teleconference - filed by Actavis Elizabeth LLC, Actavis Inc.. (Vrana, Robert) (Entered: 03/09/2016)
1102016-03-14 ORAL ORDER: IT IS HEREBY ORDERED THAT (1) Defendant's Motion to Dismiss for Lack of Standing (C.A. No. 14-1487 D.I. 62) is DENIED WITHOUT PREJUDICE to renew, consistent with the procedures the Court set out during the March 11th discovery teleconference; (2) oral argument on the pending Motion for Judgment on the Pleadings (C.A. No. 15-150 D.I. 70) and Motion to Stay (C.A. No. 15-151 D.I. 72) will be held on April 19, 2016 beginning at 1:00 p.m. -- each side will be allocated one (1) hour; and (3) the claim construction hearing scheduled for June 6, 2016 is CANCELLED by agreement of the parties. ORDERED by Judge Leonard P. Stark on 3/14/16. Associated Cases: 1:15-cv-00150-LPS, 1:15-cv-00151-LPS (ntl) (Entered: 03/14/2016)
1112016-03-17 NOTICE to Take Deposition of Peter Waibel filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC.(Vrana, Robert) (Entered: 03/17/2016)
1122016-03-17 Official Transcript of Telephone Conference held on March 11, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/7/2016. Redacted Transcript Deadline set for 4/18/2016. Release of Transcript Restriction set for 6/15/2016.(bpg) (Entered: 03/17/2016)
1132016-03-22 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding CORRECTED Version of Letter dated March 8th, 2016. - re (130 in 1:15-cv-00151-LPS, 107 in 1:15-cv-00150-LPS, 43 in 1:15-cv-00975-LPS, 103 in 1:14-cv-01487-LPS) Letter. (Silver, Daniel) (Entered: 03/22/2016)
1142016-03-28 NOTICE to Take Deposition of Michael Geranen on April 22, 2016 filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 03/28/2016)
1152016-03-28 NOTICE to Take Deposition of Shirish Shah on April 15, 2016 filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 03/28/2016)
1162016-03-28 Letter to Chief Judge Leonard P. Stark from Stamatios Stamoulis regarding renewed motion to dismiss - re (46 in 1:15-cv-00151-LPS) Oral Order,,, (40 in 1:15-cv-00150-LPS) Oral Order,,,. (Stamoulis, Stamatios) (Entered: 03/28/2016)
1172016-03-28 NOTICE OF SERVICE of Plaintiff's First Amended Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(l) filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation, Mitsui Sugar Co., Ltd..(Silver, Daniel) (Entered: 03/28/2016)
1182016-03-28 Joint PROPOSED ORDER Request for Issuance of an Order Permitting Taking of Depositions in Japan by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation, Mitsui Sugar Co., Ltd.. (Silver, Daniel) (Entered: 03/28/2016)
1192016-03-29 ORDER regarding request for issuance of an Order to take deposition in Japan. Signed by Judge Leonard P. Stark on 3/29/16. Associated Cases: 1:14-cv-01487-LPS, 1:15-cv-00150-LPS, 1:15-cv-00151-LPS, 1:15-cv-00975-LPS (ntl) (Entered: 03/29/2016)
1202016-04-05 [SEALED] NOTICE to Take Deposition of Plaintiffs Pursuant to Fed. R. Civ. P. 30(b)(6) on April 22, 2016 filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC.(Vrana, Robert) (Entered: 04/05/2016)
1212016-04-07 STIPULATION TO EXTEND TIME for the Parties to Supplement the Identification of all Accused Products and all Invalidity References and Contentions to May 9, 2016 - filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Actavis Elizabeth LLC, Actavis Inc., Apotex Corp., Apotex Inc., Ezra Ventures LLC. (Vrana, Robert) (Entered: 04/07/2016)
1222016-04-12 NOTICE OF SERVICE of Plaintiffs' First Amended Responses to Defendants' First Set of Common Interrogatories to Plaintiffs (Nos. 1-13) filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation, Mitsui Sugar Co., Ltd..(Silver, Daniel) (Entered: 04/12/2016)
1232016-04-12 REDACTED VERSION of (54 in 1:15-cv-00975-LPS, 145 in 1:15-cv-00151-LPS, 120 in 1:15-cv-00150-LPS, 117 in 1:14-cv-01487-LPS) Notice to Take Deposition, of Plaintiffs Pursuant to Fed. R. Civ. P. 30(b)(6) by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC. (Vrana, Robert) (Entered: 04/12/2016)
1242016-04-13 NOTICE of Subpoena to Massachusetts Institute of Technology by Ezra Ventures LLC (Attachments: # 1 Subpoena - Massachusetts Institute of Technology, # 2 Attachment A to Subpoena)(Stamoulis, Stamatios) (Entered: 04/13/2016)
1252016-04-13 SUBPOENA Returned Executed as to Massachusetts Institute of Technology on April 11, 2016 (Stamoulis, Stamatios) (Entered: 04/13/2016)
1262016-04-21 NOTICE to Take Deposition of Thomas Watson on April 22, 2016 filed by Actavis Elizabeth LLC, Actavis Inc., Apotex Corp., Apotex Inc., Ezra Ventures LLC, HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc..(Vrana, Robert) (Entered: 04/21/2016)
1272016-04-22 NOTICE to Take Deposition of Robert Gleeson on May 17, 2016 filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC.(Vrana, Robert) (Entered: 04/22/2016)
1282016-04-22 NOTICE to Take Deposition of Madhu Pudipeddi on May 18, 2016 filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC.(Vrana, Robert) (Entered: 04/22/2016)
1292016-04-22 NOTICE to Take Deposition of Kristen Smith-Harrington on April 29, 2016 filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC.(Vrana, Robert) (Entered: 04/22/2016)
1302016-04-22 NOTICE to Take Deposition of Colleen Ruegger on May 5, 2016 filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC.(Vrana, Robert) (Entered: 04/22/2016)
1312016-04-22 NOTICE to Take Deposition of Shreeram Aradhye on May 6, 2016 filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC.(Vrana, Robert) (Entered: 04/22/2016)
1322016-04-23 [SEALED] NOTICE OF SERVICE of Third Party Subpoenas and Notice of Deposition filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 04/23/2016)
1332016-04-23 [SEALED] NOTICE OF SERVICE of Third Party Subpoenas and Notice of Deposition filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 04/23/2016)
1342016-04-23 [SEALED] NOTICE OF SERVICE of Third Party Subpoenas and Notice of Deposition filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 04/23/2016)
1352016-04-23 [SEALED] NOTICE OF SERVICE of Third Party Subpoenas and Notice of Deposition filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 04/23/2016)
1362016-04-23 [SEALED] NOTICE OF SERVICE of Third Party Subpoenas and Notice of Deposition filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 04/23/2016)
1372016-04-23 [SEALED] NOTICE OF SERVICE of Third Party Subpoenas and Notice of Deposition filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 04/23/2016)
1382016-04-29 Official Transcript of Oral Argument Hearing held on April 19, 2016 before Chief Judge Leonard P. Stark. Court Reporter Taneha Carroll of Hawkins Reporting Service, Telephone (302) 658-6697. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 5/20/2016. Redacted Transcript Deadline set for 5/31/2016. Release of Transcript Restriction set for 7/28/2016.(bpg) (Entered: 04/29/2016)
1392016-05-02 NOTICE to Take Deposition of Hiromi Okatake on May 3, 2016 filed by Actavis Elizabeth LLC, Actavis Inc.(Vrana, Robert) Modified on 5/3/2016 (ntl). (Entered: 05/02/2016)
1402016-05-02 NOTICE to Take Deposition of Ryoji Hirose on May 13, 2016 filed by Actavis Elizabeth LLC, Actavis Inc..(Vrana, Robert) (Entered: 05/02/2016)
1412016-05-03 REDACTED VERSION of 132 Notice of Service, of Third Party Subpoenas and Notice of Deposition by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 05/03/2016)
1422016-05-03 REDACTED VERSION of 133 Notice of Service, of Third Party Subpoenas and Notice of Deposition by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 05/03/2016)
1432016-05-03 REDACTED VERSION of 134 Notice of Service, DI 142 - Novartis/Ezra - REDACTED Version of Notice of Third Party Subpoena and Notice of Deposition (Chemo Group - NJ) (20160503) by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 05/03/2016)
1442016-05-03 REDACTED VERSION of 135 Notice of Service, of Third Party Subpoenas and Notice of Deposition by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 05/03/2016)
1452016-05-03 REDACTED VERSION of 136 Notice of Service, of Third Party Subpoenas and Notice of Deposition by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 05/03/2016)
1462016-05-03 REDACTED VERSION of 137 Notice of Service, of Third Party Subpoenas and Notice of Deposition by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 05/03/2016)
1472016-05-03 Joint STIPULATION TO EXTEND TIME for the Parties to Supplement the Identification of all Accused Products and all Invalidity References and Contentions to May 16, 2016 - filed by HEC Pharm Co. Ltd.. (Stamoulis, Stamatios) (Entered: 05/03/2016)
1482016-05-05 NOTICE OF SERVICE of Defendants' Second Set of Common Requests for the Production of Documents and Things to Plaintiffs (Nos. 71-81), Defendants' First Set of Joint Requests for Admission as to the Authenticity of Documents and Things to Defendants (Nos. 1-11), Defendants' First Set of Joint Requests for Admission to Plaintiffs and Defendants' Third Set of Common Interrogatories to Plaintiffs (Nos. 16-25) filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC.(Vrana, Robert) (Entered: 05/05/2016)
1492016-05-09 NOTICE of Subpoena Directed to Karen DeBenedictis by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC (Attachments: # 1 Subpoena to Testify)(Vrana, Robert) (Entered: 05/09/2016)
1502016-05-13 NOTICE of Change of Address by Daniel M. Silver (Silver, Daniel) (Entered: 05/13/2016)
1512016-05-13 AMENDED DOCUMENT by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. Amendment to 114 Notice to Take Deposition of Michael Geranen. (Silver, Daniel) (Entered: 05/13/2016)
1522016-05-13 AMENDED DOCUMENT by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. Amendment to 115 Notice to Take Deposition of Shirish Shah. (Silver, Daniel) (Entered: 05/13/2016)
1532016-05-13 [SEALED] NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Defendant Ezra Ventures, LLC by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 05/13/2016)
1542016-05-16 NOTICE OF SERVICE of (1) Plaintiffs' Amended Preliminary Infringement Contentions for Defendants and (2) Plaintiffs' Amended Responses to Defendants' Invalidity Contentions filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation, Mitsui Sugar Co., Ltd..(Silver, Daniel) (Entered: 05/16/2016)
1552016-05-16 NOTICE OF SERVICE of Defendants' Amended Responses and Objections to Plaintiffs' First Set of Common Interrogatories 1-5 filed by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC.(Vrana, Robert) (Entered: 05/16/2016)
1562016-05-17 MOTION for Pro Hac Vice Appearance of Attorney Paul J. Kremer - filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation, Mitsui Sugar Co., Ltd.. (Attachments: # 1 Certification for Paul J. Kremer)(Silver, Daniel) (Entered: 05/17/2016)
1572016-05-17 NOTICE OF SERVICE of Plaintiffs' Second Amended Responses to Defendants' First Set of Common Interrogatories to Plaintiffs (Nos. 1, 3, 6, 7, and 8) filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation, Mitsui Sugar Co., Ltd..(Silver, Daniel) (Entered: 05/17/2016)
1582016-05-18 MOTION for Pro Hac Vice Appearance of Attorney Andrew Blythe, Nao Takada, Barish Ozdamar, Beatrice Hahn, James Barnao and Michael A. Valek - filed by Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certifications for Andrew Blythe, Nao Takada, Barish Ozdamar, Beatrice Hahn, James Barnao and Michael A. Valek)(Silver, Daniel) (Entered: 05/18/2016)
1592016-05-25 NOTICE of Subpoenas by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation (Silver, Daniel) (Entered: 05/25/2016)
1602016-06-06 NOTICE OF SERVICE of (1) Plaintiffs Responses to Defendants Second Set of Common Requests for the Production of Documents and Things to Plaintiffs (Nos. 71-81), (2) Plaintiffs Responses to Defendants Third Set of Common Interrogatories to Plaintiffs (Nos. 16-25), (3) Plaintiffs Responses to Defendants First Set of Joint Requests for Admission as to the Authenticity of Documents and Things to Defendants (Nos. 1-11), (4) Plaintiffs Responses to Defendants First Set of Joint Requests for Admission (Nos. 1-45) and (5) Plaintiffs Second Amended and Supplemental Initial Disclosures Pursuant to FED. R. CIV. P. 26(a)(1) filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation, Mitsui Sugar Co., Ltd..(Silver, Daniel) (Entered: 06/06/2016)
1612016-06-08 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Scheduling of a Discovery Teleconference. (Silver, Daniel) (Entered: 06/08/2016)
1622016-06-23 ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for July 29, 2016 at 2:15 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than July 19, 2016, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than July 21, 2016, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 6/23/16. (ntl) (Entered: 06/23/2016)
1632016-06-23 MOTION for Pro Hac Vice Appearance of Attorney Brent E. Batzer - filed by Ezra Ventures LLC. (Stamoulis, Stamatios) (Entered: 06/23/2016)
1642016-07-19 Letter to The Honorable Leonard P. Stark from Benjamin A. Smyth, Esq. regarding Teleconference Scheduled for July 29, 2016. (Smyth, Benjamin) (Entered: 07/19/2016)
1652016-07-19 Joint PROPOSED ORDER to Amend Schedule for Certain Expert Discovery Dates re (22 in 1:14-cv-01487-LPS) Scheduling Order,,,, by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC. (Vrana, Robert) (Entered: 07/19/2016)
1662016-07-21 Joint PROPOSED ORDER on Briefing Schedule for Renewed Motion to Dismiss by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC. (Vrana, Robert) (Entered: 07/21/2016)
1672016-07-22 ORAL ORDER: At the request of counsel, IT IS HEREBY ORDERED that the discovery teleconference scheduled for July 29, 2016 is CANCELLED. ORDERED by Judge Leonard P. Stark on 7/22/16. (ntl) (Entered: 07/22/2016)
1682016-07-22 MOTION to Dismiss Based upon [Defendants' Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing] - filed by Ezra Ventures LLC. (Attachments: # 1 Text of Proposed Order, # 2 Rule 7.1.1 Statement)(Vrana, Robert) (Entered: 07/22/2016)
1692016-07-22 [SEALED] OPENING BRIEF in Support re 168 MOTION to Dismiss Based upon [Defendants' Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing] filed by Ezra Ventures LLC.Answering Brief/Response due date per Local Rules is 8/8/2016. (Attachments: # 1 Certificate of Service)(Vrana, Robert) (Entered: 07/22/2016)
1702016-07-22 [SEALED] DECLARATION re (82 in 1:15-cv-00975-LPS) MOTION to Dismiss Based upon [Defendants' Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing], (180 in 1:15-cv-00151-LPS) MOTION to Dismiss Based upon [Defendants' Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing], (181 in 1:15-cv-00151-LPS) Opening Brief in Support, (168 in 1:15-cv-00150-LPS) MOTION to Dismiss Based upon [Defendants' Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing], (83 in 1:15-cv-00975-LPS) Opening Brief in Support, [Declaration of Heather M. Schneider] by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Ezra Ventures LLC. (Attachments: # 1 Exhibit A, Part 1, # 2 Exhibit A, Part 2, # 3 Exhibit A, Part 3, # 4 Exhibit B, Part 1, # 5 Exhibit B, Part 2, # 6 Exhibit B, Part 3, # 7 Exhibit C - J, # 8 Exhibit K - M, # 9 Exhibit N - U, # 10 Exhibit V - Z, # 11 Exhibit AA - EE, # 12 Exhibit FF - MM, # 13 Certificate of Service)(Vrana, Robert) (Entered: 07/22/2016)
1712016-07-22 Letter to The Honorable Leonard P. Stark from Robert M. Vrana, Esq. regarding Copy of Defendants' Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing with supporting papers - re (84 in 1:15-cv-00975-LPS, 170 in 1:15-cv-00150-LPS, 182 in 1:15-cv-00151-LPS) Declaration,,,, (181 in 1:15-cv-00151-LPS) Opening Brief in Support, (169 in 1:15-cv-00150-LPS) Opening Brief in Support, (168 in 1:15-cv-00150-LPS) MOTION to Dismiss Based upon [Defendants' Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing], (82 in 1:15-cv-00975-LPS) MOTION to Dismiss Based upon [Defendants' Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing], (83 in 1:15-cv-00975-LPS) Opening Brief in Support, (180 in 1:15-cv-00151-LPS) MOTION to Dismiss Based upon [Defendants' Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing]. (Vrana, Robert) (Entered: 07/22/2016)
1722016-07-27 Letter to The Honorable Chief Judge Leonard P. Stark from Daniel M. Silver, Esq. regarding the Scheduling of a Discovery Teleconference. (Silver, Daniel) (Entered: 07/27/2016)
1732016-07-28 STIPULATION TO EXTEND TIME the Defendants to submit a Public Version of Their Opening Brief In Support of Defendants Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing and Declaration of Heather M. Schneider In Support of Defendants Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing to Friday, August 5, 2016 (from Friday, July 29, 2016) - filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation, Mitsui Sugar Co., Ltd.. (Silver, Daniel) (Entered: 07/28/2016)
1742016-08-01 NOTICE of Plaintiffs' Re-Notice of Deposition Under Federal Rule of Civil Procedure 30(b)(6) by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation re 137 Notice of Service, (Silver, Daniel) (Entered: 08/01/2016)
1752016-08-03 ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for August 16, 2016 at 10:00 a.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than August 8, 2016, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than August 10, 2016, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 8/3/16. (ntl) (Entered: 08/03/2016)
1762016-08-05 REDACTED VERSION of (181 in 1:15-cv-00151-LPS) Opening Brief in Support, (152 in 1:14-cv-01487-LPS) Opening Brief in Support, (169 in 1:15-cv-00150-LPS) Opening Brief in Support, (83 in 1:15-cv-00975-LPS) Opening Brief in Support, [Opening Brief in Support of Defendants' Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing] by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC. (Vrana, Robert) (Entered: 08/05/2016)
1772016-08-05 REDACTED VERSION of (84 in 1:15-cv-00975-LPS, 170 in 1:15-cv-00150-LPS, 182 in 1:15-cv-00151-LPS) Declaration,,,, (153 in 1:14-cv-01487-LPS) Declaration,,, [Declaration of Heather M. Schneider in Support of Defendants' Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing] by HEC Pharm Co. Ltd., HEC Pharm Group, HEC Pharm USA Inc., Apotex Corp., Apotex Inc., Actavis Elizabeth LLC, Actavis Inc., Ezra Ventures LLC. (Attachments: # 1 Exhibit Part 1, # 2 Exhibit Part 2, # 3 Exhibit Part 3, # 4 Exhibit Part 4, # 5 Exhibit Part 5, # 6 Exhibit Part 6, # 7 Exhibit Part 7, # 8 Exhibit Part 8)(Vrana, Robert) (Entered: 08/05/2016)
1782016-08-08 [SEALED] Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Courts August 3, 2016 Order - re 175 Order,,,,, Set Hearings,,,,. (Attachments: # 1 Exhibit A-B, # 2 Exhibit C, # 3 Exhibit D-K, # 4 Certificate of Service)(Silver, Daniel) (Entered: 08/08/2016)
1792016-08-10 [SEALED] Letter to the Honorable Leonard P. Stark from Stamatios Stamoulis regarding Dispute over Privileged Documents - re 175 Order,,,,, Set Hearings,,,,. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Stamoulis, Stamatios) (Entered: 08/10/2016)
1802016-08-10 Joint STIPULATION TO EXTEND TIME to complete briefing on Defendants' Motion To Dismiss to August 19, 2016 (Answering Brief) and September 2, 2016 (Reply Brief) - filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 08/10/2016)
1812016-08-15 REDACTED VERSION of 178 Letter, by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 08/15/2016)
1822016-08-24 Official Transcript of Telephone Conference held on August 16, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/14/2016. Redacted Transcript Deadline set for 9/26/2016. Release of Transcript Restriction set for 11/22/2016. (bpg) (Entered: 08/24/2016)
1832016-09-02 [SEALED] REPLY BRIEF re 168 MOTION to Dismiss Based upon [Defendants' Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing] filed by Ezra Ventures LLC. (Vrana, Robert) (Entered: 09/02/2016)
1842016-09-02 [SEALED] DECLARATION re 183 Reply Brief - Declaration of Ronald A. Lee - by Ezra Ventures LLC. (Attachments: # 1 Exhibit A, B and Q)(Vrana, Robert) (Entered: 09/02/2016)
1852016-09-09 REDACTED VERSION of 183 Reply Brief re 168 Motion to Dismiss Based upon [Defendants' Renewed Motion to Dismiss Novartis Pharmaceuticals Corporation and Novartis AG for Lack of Standing] by Ezra Ventures LLC. (Vrana, Robert) (Entered: 09/09/2016)
1862016-09-09 REDACTED VERSION of 184 Declaration of Ronald A. Lee by Ezra Ventures LLC. (Vrana, Robert) (Entered: 09/09/2016)
1872016-09-22 MEMORANDUM OPINION re 70 motion for judgment on the pleadings. Signed by Judge Leonard P. Stark on 9/22/16. (ntl) (Entered: 09/22/2016)
1882016-09-22 ORDER re 187 Memorandum Opinion -- 70 MOTION for Judgment on the Pleadings is DENIED. Signed by Judge Leonard P. Stark on 9/22/16. (ntl) (Entered: 09/22/2016)
1892016-10-13 Letter to The Honorable Leonard P. Stark from Bindu A. Palapura regarding request for discovery dispute conference. (Palapura, Bindu) (Entered: 10/13/2016)
1902016-10-14 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Plaintiffs Response to Apotex and Ezra's Teleconference Request. (Silver, Daniel) (Entered: 10/14/2016)
1912016-10-17 Letter to The Honorable Leonard P. Stark from Bindu A. Palapura regarding response to Plaintiffs' letter dated October 14, 2016 - re (100 in 1:15-cv-00975-LPS, 190 in 1:15-cv-00150-LPS) Letter. (Palapura, Bindu) (Entered: 10/17/2016)
1922016-10-26 ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for November 8, 2016 at 2:30 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than November 1, 2016, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than November 3, 2016, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 10/26/16. Associated Cases: 1:15-cv-00150-LPS, 1:15-cv-00975-LPS (ntl) (Entered: 10/26/2016)
1932016-11-01 [SEALED] Letter to The Honorable Leonard P. Stark from Bindu A. Palapura regarding opening discovery dispute. (Attachments: # 1 Exhibit A-K, # 2 Exhibit L, # 3 Exhibit M-S)(Palapura, Bindu) (Entered: 11/01/2016)
1942016-11-03 [SEALED] Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Response to Defendants' November 1, 2016 Letter - re (109 in 1:15-cv-00975-LPS) Letter, (193 in 1:15-cv-00150-LPS) Letter. (Attachments: # 1 Exhibit A-E, # 2 Certificate of Service)(Silver, Daniel) (Entered: 11/03/2016)
1952016-11-14 STIPULATION TO EXTEND TIME for the parties to submit a joint submission regarding the status of the Parties' dispute concerning Plaintiffs' privilege logs to November 17, 2016 - filed by Apotex Corp., Apotex Inc.. (Palapura, Bindu) (Entered: 11/14/2016)
1962016-11-17 Joint Letter to The Honorable Leonard P. Stark from Bindu A. Palapura, Esquire regarding privilege log issues. (Attachments: # 1 Exhibit A-B)(Palapura, Bindu) (Entered: 11/17/2016)
1972016-11-18 Official Transcript of Telephone Conference held on November 8, 2016 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone No. (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 12/9/2016. Redacted Transcript Deadline set for 12/19/2016. Release of Transcript Restriction set for 2/16/2017. (bpg) (Entered: 11/18/2016)
1982016-11-18 NOTICE to Take Deposition of Anthony L. DeFranco on December 9, 2016 filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation, Mitsui Sugar Co., Ltd..(Silver, Daniel) (Entered: 11/18/2016)
1992016-11-18 NOTICE to Take Deposition of John Kornak on December 16, 2016 filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation, Mitsui Sugar Co., Ltd..(Silver, Daniel) (Entered: 11/18/2016)
2002016-11-18 NOTICE to Take Deposition of Stephen P. Tanis on December 20, 2016 filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation, Mitsui Sugar Co., Ltd..(Silver, Daniel) (Entered: 11/18/2016)
2012016-11-28 NOTICE of Intent to Request Redaction by Bindu Ann George Palapura re (197 in 1:15-cv-00150-LPS) Transcript,, (Palapura, Bindu) (Entered: 11/28/2016)
2022016-12-05 NOTICE requesting Clerk to remove Nao Takada as co-counsel.. (Smyth, Benjamin) (Entered: 12/05/2016)
2032016-12-05 MOTION for Pro Hac Vice Appearance of Attorney Nao Takada - filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Mitsui Sugar Co., Ltd.. (Attachments: # 1 Certification for Nao Takada)(Smyth, Benjamin) (Entered: 12/05/2016)
2042016-12-19 NOTICE to Take Deposition of Dr. David Madigan on December 22, 2016 filed by HEC Pharm USA Inc..(Stamoulis, Stamatios) (Entered: 12/19/2016)
2052017-01-26 NOTICE to Take Deposition of Steven Tanis on January 27, 2017 filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 01/26/2017)
2062017-01-30 NOTICE to Take Deposition of Chander Raman, Ph.D. on January 31, 2017 at 8:30 am filed by Novartis AG, Novartis Pharmaceuticals Corporation, Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co., Ltd..(Silver, Daniel) (Entered: 01/30/2017)
2072017-01-30 ORAL ORDER: Having reviewed the parties' joint letter (D.I. 196), IT IS HEREBY ORDERED that no relief is warranted at this time. Plaintiffs agreed to supplement their privilege logs by December 5, 2017. Should Defendants have specific objections regarding the supplemented privilege logs, they may use the discovery-dispute resolution procedures set out in the scheduling order. ORDERED by Judge Leonard P. Stark on 1/30/17. (ntl) (Entered: 01/30/2017)
2082017-02-27 Joint STIPULATION to Narrow the Issues in Dispute and Proposed Order by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 02/27/2017)
2092017-03-17 [SEALED] MEMORANDUM OPINION re pending motions. Signed by Judge Leonard P. Stark on 3/17/17. This order has been emailed to local counsel. Associated Cases: 1:14-cv-01487-LPS, 1:15-cv-00150-LPS, 1:15-cv-00151-LPS, 1:15-cv-00975-LPS (ntl) (Entered: 03/17/2017)
2102017-03-17 ORDER re (209 in 1:15-cv-00150-LPS, 230 in 1:14-cv-01487-LPS, 207 in 1:15-cv-00151-LPS, 126 in 1:15-cv-00975-LPS) Memorandum Opinion -- (151 in 1:14-cv-01487-LPS) MOTION to Dismiss is GRANTED IN PART AND DENIED IN PART; (159 in 1:14-cv-01487-LPS) Cross MOTION for Partial Summary Judgment is GRANTED IN PART AND DENIED IN PART; (172 in 1:14-cv-01487-LPS) MOTION for Leave to File a Surreply is GRANTED. Signed by Judge Leonard P. Stark on 3/17/17. Associated Cases: 1:14-cv-01487-LPS, 1:15-cv-00150-LPS, 1:15-cv-00151-LPS, 1:15-cv-00975-LPS (ntl) (Entered: 03/17/2017)
2112017-03-23 Letter to The Honorable Chief Judge Leonard P. Stark from Daniel M. Silver regarding Proposed Redactions to March 17, 2017 Memorandum Opinion - re (209 in 1:15-cv-00150-LPS, 230 in 1:14-cv-01487-LPS, 207 in 1:15-cv-00151-LPS, 126 in 1:15-cv-00975-LPS) Memorandum Opinion. (Attachments: # 1 Proposed Redactions to March 17, 2017 Memorandum Opinion)(Silver, Daniel) (Entered: 03/23/2017)
2122017-03-27 REDACTED PUBLIC VERSION of 209 Memorandum Opinion. (ntl) (Entered: 03/27/2017)
2132017-03-28 MOTION for Pro Hac Vice Appearance of Attorney Joseph M. O'Malley, Eric W. Dittmann and Yousef M. Mian - filed by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd.. (Attachments: # 1 Certifications of Joseph M. O'Malley, Eric W. Dittman and Yousef M. Mian)(Silver, Daniel) (Entered: 03/28/2017)
2142017-03-30 MOTION for Pro Hac Vice Appearance of Attorney Alex Harris - filed by Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification of Alex Harris)(Silver, Daniel) (Entered: 03/30/2017)
2152017-03-31 Joint STIPULATION To Extend Deadline to Submit Pretrial Order and Proposed Order by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 03/31/2017)
2162017-04-04 [SEALED] Proposed Pretrial Order by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation, Mitsui Sugar Co., Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13A, # 14 Exhibit 13B, # 15 Exhibit 13C, # 16 Exhibit 13D, # 17 Exhibit 14)(Silver, Daniel) (Entered: 04/05/2017)
2172017-04-10 NOTICE of Supplemental Authority by Ezra Ventures LLC (Attachments: # 1 Novartis Pharms. Corp. v. Breckenridge Pharm., Inc.)(Weinblatt, Richard) (Entered: 04/10/2017)
2182017-04-17 MEMORANDUM ORDER re (209 in 1:14-cv-01487-LPS) MOTION for Summary Judgment is DENIED as moot; (216 in 1:14-cv-01487-LPS) MOTION to Preclude is DENIED as moot; (208 in 1:14-cv-01487-LPS) MOTION to Preclude is DENIED; Rulings on the various motions in limine as set forth in the PTO; the Court allocates a maximum of eleven (11) hours per side (see trial schedule). Signed by Judge Leonard P. Stark on 4/17/17. Associated Cases: 1:14-cv-01487-LPS, 1:15-cv-00150-LPS, 1:15-cv-00151-LPS, 1:15-cv-00975-LPS (ntl) (Entered: 04/17/2017)
2192017-04-27 ORAL ORDER: Having reviewed the parties' joint status report (C.A. No. 14-1487 D.I. 292), IT IS HEREBY ORDERED that Plaintiffs' responsive brief to Actavis' motion for entry of judgment (D.I. 291), and any cross-motion with opening brief, shall be filed no later than May 9, 2017. Given the parties' cancellation of the trial, the Court sees no reason for any further delay in the briefing of that motion. IT IS FURTHER ORDERED that the parties to all of the actions in which this Order is being docketed shall cooperate to file a single, joint status report, which shall include a clear indication as to the status of each of these actions, what remains to be done in each action, and when it should be done. The status report shall be filed no later than May 1, 2017. The Court will hold a status teleconference with all of the parties to all of these actions on May 4 at 4:30 p.m., with Plaintiffs' counsel to initiate the call to (302) 573-4571. ORDERED by Judge Leonard P. Stark on 4/27/17. Associated Cases: 1:14-cv-01487-LPS, 1:15-cv-00150-LPS, 1:15-cv-00151-LPS, 1:15-cv-00975-LPS (ntl) (Entered: 04/27/2017)
2202017-05-01 Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Joint Status Report - re (217 in 1:15-cv-00151-LPS, 219 in 1:15-cv-00150-LPS, 293 in 1:14-cv-01487-LPS, 135 in 1:15-cv-00975-LPS) Order Setting Teleconference,,,,. (Silver, Daniel) (Entered: 05/01/2017)
2212017-05-05 Joint STIPULATION For Resolution of Remaining Issues in Dispute and Proposed Order by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 05/05/2017)
2222017-05-18 Official Transcript of Pretrial Conference held on April 18, 2017 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 6/8/2017. Redacted Transcript Deadline set for 6/19/2017. Release of Transcript Restriction set for 8/16/2017.(bpg) (Entered: 05/18/2017)
2232017-05-18 Official Transcript of Oral Argument Hearing held on May 4, 2017 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 6/8/2017. Redacted Transcript Deadline set for 6/19/2017. Release of Transcript Restriction set for 8/16/2017. (bpg) (Entered: 05/18/2017)
2242017-05-31 MEMORANDUM ORDER re parties' submission of a proposed final judgment. Signed by Judge Leonard P. Stark on 5/31/17. Associated Cases: 1:14-cv-01487-LPS, 1:15-cv-00150-LPS, 1:15-cv-00151-LPS, 1:15-cv-00975-LPS (ntl) (Entered: 05/31/2017)
2252017-06-02 PROPOSED ORDER Final Judgment by Mitsubishi Tanabe Pharma Corporation, Mitsui Sugar Co. Ltd., Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 06/02/2017)
2262017-06-09 FINAL JUDGMENT (See document for further details), ***Civil Case Terminated. Signed by Judge Leonard P. Stark on 6/8/17. (ntl) (Entered: 06/09/2017)
2272017-06-16 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,604,229. (etg) (Entered: 06/16/2017)
2282017-07-07 NOTICE OF APPEAL to the Federal Circuit of 187 Memorandum Opinion, 210 Order,, 209 Memorandum Opinion . Appeal filed by Ezra Ventures LLC. (Stamoulis, Stamatios) (Entered: 07/07/2017)
2292017-07-11 NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re 228 Notice of Appeal (Federal Circuit) filed by Ezra Ventures LLC. USCA Case Number 17-2284. (ntl) (Entered: 07/12/2017)